📊 IBIO Key Takeaways
Is iBio, Inc. (IBIO) a Good Investment?
iBio is a pre-commercial stage pharmaceutical company with only $100K in annual revenue but $14.7M in operating losses, generating negative free cash flow of -$11.5M. While the company maintains a strong liquidity position ($28.7M cash, zero debt, 9.04x current ratio), at the current burn rate it has less than 2 years of runway before capital depletion, with no demonstrated path to profitability.
Fundamentals show negligible revenue against very large operating losses and deeply negative free cash flow, producing extreme negative margins. While liquidity is strong and the balance sheet is debt‑free, sustainability depends on rapidly reducing burn and establishing recurring revenue, otherwise external financing risk is high.
Why Buy iBio, Inc. Stock? IBIO Key Strengths
- Exceptional liquidity with $28.7M in cash and 9.04x current ratio
- Zero debt burden provides operational flexibility and no interest obligations
- Reasonable equity base of $56.6M provides financial cushion for continued R&D
- Revenue growth of 77.8% YoY, though from negligible base
- Strong liquidity (cash $28.67M; current ratio 9.04x)
- Debt‑free balance sheet (D/E 0.00x)
- EPS loss narrowed YoY, hinting at some cost discipline
IBIO Stock Risks: iBio, Inc. Investment Risks
- Unsustainable cash burn of $14.7M annually against zero meaningful revenue
- Negative operating cash flow of -$10.9M with runway of less than 24 months at current burn
- Gross profit anomaly ($2.2M on $100K revenue) suggests data quality or accounting irregularities
- Pre-commercial stage with no evidence of commercial traction or clear monetization path
- Highly speculative biotech venture dependent entirely on pipeline success with no near-term revenue visibility
- Large, persistent operating losses and negative FCF (OCF -$10.91M; FCF -$11.45M)
- Tiny revenue base and anomalous gross margin suggest low-quality, non-recurring mix
- Potential dilution/financing need if burn continues
Key Metrics to Watch
- Monthly cash burn rate and updated runway projections
- Path to clinical/regulatory milestones and commercialization timeline
- Gross margin normalization and revenue acceleration to validate business model
- Operating cash burn vs cash runway
- Recurring revenue growth and gross margin quality
iBio, Inc. (IBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.04x current ratio provides a solid financial cushion.
IBIO Profit Margin, ROE & Profitability Analysis
IBIO vs Healthcare Sector: How iBio, Inc. Compares
How iBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is iBio, Inc. Stock Overvalued? IBIO Valuation Analysis 2026
Based on fundamental analysis, iBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
iBio, Inc. Balance Sheet: IBIO Debt, Cash & Liquidity
IBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: iBio, Inc.'s revenue has grown significantly by 78% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.50 indicates the company is currently unprofitable.
IBIO Revenue Growth, EPS Growth & YoY Performance
IBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | N/A | -$4.0M | $-0.09 |
| Q1 2026 | N/A | -$4.0M | $-0.11 |
| Q3 2025 | N/A | -$3.2M | $-0.49 |
| Q2 2025 | $50.0K | -$4.0M | $-0.48 |
| Q1 2025 | N/A | -$4.0M | $-0.46 |
| Q3 2024 | N/A | N/A | $-0.85 |
| Q2 2024 | N/A | N/A | $-4.42 |
| Q1 2024 | N/A | N/A | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
iBio, Inc. Dividends, Buybacks & Capital Allocation
IBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for iBio, Inc. (CIK: 0001420720)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IBIO
What is the AI rating for IBIO?
iBio, Inc. (IBIO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IBIO's key strengths?
Claude: Exceptional liquidity with $28.7M in cash and 9.04x current ratio. Zero debt burden provides operational flexibility and no interest obligations. ChatGPT: Strong liquidity (cash $28.67M; current ratio 9.04x). Debt‑free balance sheet (D/E 0.00x).
What are the risks of investing in IBIO?
Claude: Unsustainable cash burn of $14.7M annually against zero meaningful revenue. Negative operating cash flow of -$10.9M with runway of less than 24 months at current burn. ChatGPT: Large, persistent operating losses and negative FCF (OCF -$10.91M; FCF -$11.45M). Tiny revenue base and anomalous gross margin suggest low-quality, non-recurring mix.
What is IBIO's revenue and growth?
iBio, Inc. reported revenue of $100.0K.
Does IBIO pay dividends?
iBio, Inc. does not currently pay dividends.
Where can I find IBIO SEC filings?
Official SEC filings for iBio, Inc. (CIK: 0001420720) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IBIO's EPS?
iBio, Inc. has a diluted EPS of $-0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, iBio, Inc. has a STRONG SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IBIO stock overvalued or undervalued?
Valuation metrics for IBIO: ROE of -26.0% (sector avg: 15%), net margin of -14,713.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IBIO stock in 2026?
Our dual AI analysis gives iBio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IBIO's free cash flow?
iBio, Inc.'s operating cash flow is $-10.9M, with capital expenditures of $548.0K. FCF margin is -11,454.0%.
How does IBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14,713.0% (avg: 12%), ROE -26.0% (avg: 15%), current ratio 9.04 (avg: 2).